Akouos (Akouos) Treasury Stock : $0.00 Mil (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Akouos Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Akouos's treasury stock for the quarter that ended in Sep. 2022 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Akouos Treasury Stock Historical Data

The historical data trend for Akouos's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akouos Treasury Stock Chart

Akouos Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Treasury Stock

Akouos Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Treasury Stock	Get a 7-Day Free Trial											-	-	-	-	-

Akouos Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Akouos (Akouos) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 200, Boston, MA, USA, 02210

Website

https://www.akouos.com

Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.

Executives

Kearny Acquisition Corp	10 percent owner	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman	officer: Chief Operating Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi	officer: Chief Financial Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi	10 percent owner	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p.	10 percent owner	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston	director, 10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102